Intercept Pharmaceuticals Balance Sheet Health
Financial Health criteria checks 5/6
Intercept Pharmaceuticals has a total shareholder equity of $67.2M and total debt of $333.0M, which brings its debt-to-equity ratio to 495.7%. Its total assets and total liabilities are $504.1M and $436.9M respectively.
Key information
495.7%
Debt to equity ratio
US$333.04m
Debt
| Interest coverage ratio | n/a |
| Cash | US$433.60m |
| Equity | US$67.19m |
| Total liabilities | US$436.90m |
| Total assets | US$504.09m |
Recent financial health updates
Recent updates
Financial Position Analysis
Short Term Liabilities: ICPT *'s short term assets ($490.5M) exceed its short term liabilities ($207.1M).
Long Term Liabilities: ICPT *'s short term assets ($490.5M) exceed its long term liabilities ($229.8M).
Debt to Equity History and Analysis
Debt Level: ICPT * has more cash than its total debt.
Reducing Debt: ICPT * had negative shareholder equity 5 years ago, but is now positive and has therefore improved.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ICPT * has sufficient cash runway for more than 3 years based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ICPT * has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.